Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? - PubMed (original) (raw)
. 2012 Aug;27(8):2494-502.
doi: 10.1093/humrep/des213. Epub 2012 Jun 12.
Affiliations
- PMID: 22693172
- DOI: 10.1093/humrep/des213
Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
Tina B Eilertsen et al. Hum Reprod. 2012 Aug.
Abstract
Study question: Can anti-Müllerian hormone (AMH) level replace the morphologic description in the diagnosis of polycystic ovary syndrome (PCOS) and what is the relationship between AMH and different diagnostic criteria of PCOS?
Summary answer: AMH may be a good substitute for polycystic ovarian morphology (PCOM) in diagnosing PCOS.
What is known already: AMH has been suggested as an alternative to antral follicle count (AFC) in diagnosing PCOS. Cut-off values for AMH studied so far show an acceptable specificity but a rather poor sensitivity, leaving up to one-third of PCOS women undiagnosed.
Study design, size, duration: We used data from a cross-sectional, case-control study on women with prior preterm birth and their controls, i.e. women with prior full-term birth. Among 262 women, 56 met the Rotterdam criteria (PCOS-R) and 44 the Androgen Excess-PCOS Society (PCOS-AES) criteria of PCOS.
Participants/materials, setting, methods: Fasting blood samples were collected, a transvaginal ultrasound investigation and a clinical examination were performed. PCOS-R and PCOS-AES were re-diagnosed by replacing PCOM with AMH. Main outcome measures were the prevalence of PCOS, PCOM, hirsutism, oligoamenorrhoea and serum levels of AMH and androgens.
Main results and the role of chance: When replacing PCOM with AMH, the specificity and sensitivity for identifying PCOS were 97.1 and 94.6% according to the PCOS-R criteria and 97.2 and 95.5% according to the PCOS-AES criteria, respectively, at an AMH cut-off value of 20 pmol/l.
Limitations, reasons for caution: The results need to be confirmed when international standards and methods for AMH measurements are established.
Wider implications of the findings: AMH may be a good substitute for PCOM in diagnosing PCOS.
Study funding/competing interest(s): This study was financed by the Cooperative of Central Norway Regional Health Authority and Norwegian University of Science and Technology. The authors have no interests to disclose.
Trial registration number: This study is registered at www.clinicaltrials.gov as NCT01355536.
Similar articles
- Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
Dewailly D, Alebić MŠ, Duhamel A, Stojanović N. Dewailly D, et al. Hum Reprod. 2014 Nov;29(11):2536-43. doi: 10.1093/humrep/deu242. Epub 2014 Sep 29. Hum Reprod. 2014. PMID: 25267785 - The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A. Lauritsen MP, et al. Hum Reprod. 2014 Apr;29(4):791-801. doi: 10.1093/humrep/det469. Epub 2014 Jan 16. Hum Reprod. 2014. PMID: 24435776 - Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.
Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF. Dewailly D, et al. Hum Reprod Update. 2014 May-Jun;20(3):334-52. doi: 10.1093/humupd/dmt061. Epub 2013 Dec 16. Hum Reprod Update. 2014. PMID: 24345633 - [Anti-Mullerian hormone- its role in the pathogenesis of the polycystic ovary syndrome].
Parahuleva N, Pehlivanov B, Dimitrakova E, Malinova M, Mladenova M. Parahuleva N, et al. Akush Ginekol (Sofiia). 2012;51(6):22-6. Akush Ginekol (Sofiia). 2012. PMID: 23390860 Review. Bulgarian.
Cited by
- Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis.
Piltonen TT, Viita-Aho J, Saarela U, Melin J, Forslund M. Piltonen TT, et al. Semin Reprod Med. 2024 Mar;42(1):49-59. doi: 10.1055/s-0044-1786731. Epub 2024 May 22. Semin Reprod Med. 2024. PMID: 38776986 Free PMC article. Review. - Efficacy of serum anti-mullerian hormone (AMH) levels for prediction of polycystic ovary syndrome (PCOS) and its association with clinical, biochemical and hormonal parameters.
Sumji S, Bhat A, Rashid A, Bashir R, Wani IA, Vasudevan V, Sehar T, Ganie MA. Sumji S, et al. Indian J Clin Biochem. 2023 Oct;38(4):457-465. doi: 10.1007/s12291-022-01058-4. Epub 2022 Sep 6. Indian J Clin Biochem. 2023. PMID: 37746534 Free PMC article. - The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome.
Sivanandy MS, Ha SK. Sivanandy MS, et al. Diagnostics (Basel). 2023 Feb 27;13(5):907. doi: 10.3390/diagnostics13050907. Diagnostics (Basel). 2023. PMID: 36900051 Free PMC article. Review. - The diagnostic performance of antimullerian hormone for polycystic ovarian syndrome and polycystic ovarian morphology.
Vural F, Vural B, Kardaş E, Ertürk Coşkun AD, Yildirim İ. Vural F, et al. Arch Gynecol Obstet. 2023 Apr;307(4):1083-1090. doi: 10.1007/s00404-022-06874-w. Epub 2022 Dec 24. Arch Gynecol Obstet. 2023. PMID: 36565362 - An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options.
Islam H, Masud J, Islam YN, Haque FKM. Islam H, et al. Womens Health (Lond). 2022 Jan-Dec;18:17455057221117966. doi: 10.1177/17455057221117966. Womens Health (Lond). 2022. PMID: 35972046 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous